Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma

NCT06058793 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06058793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06058793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
December 13, 2023
Completion date
December 12, 2025
Enrollment
138 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

liposarcoma, dedifferentiated